File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

postgraduate thesis: Review of clinical benefits and cost effectiveness of epidermal growthfactor receptor-tyrosine kinase inhibitor (EGFR-TKI) as first linetreatment for patients with advanced non-small cell lung cancer(NSCLC)

TitleReview of clinical benefits and cost effectiveness of epidermal growthfactor receptor-tyrosine kinase inhibitor (EGFR-TKI) as first linetreatment for patients with advanced non-small cell lung cancer(NSCLC)
Authors
Choi, Ho-ying.蔡可盈.
Issue Date2011
PublisherThe University of Hong Kong (Pokfulam, Hong Kong)
Citation
Choi, H. [蔡可盈]. (2011). Review of clinical benefits and cost effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) as first line treatment for patients with advanced non-small cell lung cancer (NSCLC). (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4693532
DegreeMaster of Public Health
SubjectLungs - Cancer - Treatment.
Epidermal growth factor - Receptors.
Protein kinases - Inhibitors.
Dept/ProgramPublic Health
Persistent Identifierhttp://hdl.handle.net/10722/145717
HKU Library Item IDb4693532

 

DC FieldValueLanguage
dc.contributor.authorChoi, Ho-ying.-
dc.contributor.author蔡可盈.-
dc.date.issued2011-
dc.identifier.citationChoi, H. [蔡可盈]. (2011). Review of clinical benefits and cost effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) as first line treatment for patients with advanced non-small cell lung cancer (NSCLC). (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4693532-
dc.identifier.urihttp://hdl.handle.net/10722/145717-
dc.languageeng-
dc.publisherThe University of Hong Kong (Pokfulam, Hong Kong)-
dc.relation.ispartofHKU Theses Online (HKUTO)-
dc.rightsThe author retains all proprietary rights, (such as patent rights) and the right to use in future works.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.source.urihttp://hub.hku.hk/bib/B46935320-
dc.subject.lcshLungs - Cancer - Treatment.-
dc.subject.lcshEpidermal growth factor - Receptors.-
dc.subject.lcshProtein kinases - Inhibitors.-
dc.titleReview of clinical benefits and cost effectiveness of epidermal growthfactor receptor-tyrosine kinase inhibitor (EGFR-TKI) as first linetreatment for patients with advanced non-small cell lung cancer(NSCLC)-
dc.typePG_Thesis-
dc.identifier.hkulb4693532-
dc.description.thesisnameMaster of Public Health-
dc.description.thesislevelMaster-
dc.description.thesisdisciplinePublic Health-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.5353/th_b4693532-
dc.date.hkucongregation2011-
dc.identifier.mmsid991032516539703414-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats